Fig. 2
From: Epigenetic targets of Janus kinase inhibitors are linked to genetic risks of rheumatoid arthritis
Distinctive transcriptomic signatures induced by therapeutic agents. a Principal component analysis (PCA) of gene expression levels for the top 1000 variable genes. Samples obtained at 24 h (left) and 7 days (right) after treatment were projected onto PC1/PC2. Numbers in parentheses indicate the contribution ratio (percentage of variation) of the first two PCs. b Heatmap illustrating the regression coefficient of the modules identified by weighted gene correlation network analysis (WGCNA) in comparing different treatment conditions (left). Temporal transcriptomic changes in representative modules are shown in line graphs (right). Dots in line plots represent the mean ADA adalimumab, BARI baricitinib, CPM count per million, M module, NS non-stimulated, NT non-treated, PC principal component, TOFA tofacitinib, UPA upadacitinib, 24 h 24 h, 7d 7 days